iHuman
7 hedge funds and large institutions have $7.8M invested in iHuman in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
40% more funds holding
Funds holding: 5 → 7 (+2)
0.08% more ownership
Funds ownership: 4.91% → 4.99% (+0.08%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less capital invested
Capital invested by funds: $8.47M → $7.8M (-$670K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$32.1K |
| 2 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$21.3K |
| 3 |
Renaissance Technologies
New York
|
+$6.69K |
| 4 |
State Street
Boston,
Massachusetts
|
+$2.76K |
| 5 |
Morgan Stanley
New York
|
+$1.36K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$172 |
IH Hedge Fund Activity: Q2 2023 in Review
7 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in iHuman (IH) for Q2 2023, worth a combined $7.8M — down 7.9% from $8.47M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new IH positions and 1 closed out — a net gain of 2 holders — while 3 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $32.1K. The largest seller was UBS Group, exiting entirely with an estimated $172 sold.
- 7 institutional investors held iHuman (IH) as of Q2 2023, up from 5 in Q1 2023.
- Funds reported $7.8M of iHuman stock for Q2 2023, down 7.9% quarter-over-quarter.
- 3 funds opened new iHuman positions in Q2 2023 and 1 closed out, a net change of +2 holders.
- The largest iHuman buyer in Q2 2023 was Citadel Advisors, an estimated $32.1K added.
- The largest iHuman seller in Q2 2023 was UBS Group, an estimated $172 sold.
Based on aggregated 13F filings for Q2 2023.